A radioimmunoassay for plasma ethinyl oestradiol, featuring an immunosorbent extraction procedure, is described. Ethinyl oestradiol (EE 2 ) was extracted using a non-specific, anti-oestrogen serum, raised to an oestradiol-17-hemisuccinate conjugate. The antiserum, coupled to microcrystalline cellulose, selectively extracted EE 2 but not norethisterone (NE), thus conferring specificity on a radioimmunoassay which has previously exhibited unacceptably high cross-reactivity with the synthetic progestagen, norethisterone, often used concomitantly with ethinyl oestradiol. This radioimmunoassay was shown to fulfil accepted assay validation criteria. Levels in subjects not receiving EE2 were less than 25 prnol/L Circulating concentrations of EE 2 could therefore be accurately determined in patients receiving low-dose combined preparations (EE 2 35 fLg; NE 500 fLg).
Ethinyl oestradiol (EE 2 ) became generally available in the late 1930s and since that time has become established as one of the most widely used oestrogenic components of combined oral contraceptive preparations. However, the thromboembolic sideeffects known to be associated with oestrogen therapy-2 have led to the introduction of low-dose formulations. Bioavailability and pharmacokinetic studies require that an assay should have the sensitivity required to determine the low circulating EE 2 concentrations achieved after administration of these new preparations. Since EE 2 is incorporated in formulations containing comparatively large amounts of synthetic progestagens, the assay procedure must also be sufficiently specific to eliminate any interference caused by these compounds. Such specificity has been achieved in the assay reported here using an 'immunosorbent extraction' technique.
Material and methods
Dextran T-70 was supplied by Pharmacia Ltd, London, UK. Cyanogen bromide was purchased from Aldrich Chemical Co Ltd, Gillingham, Dorset, UK. Microcrystalline cellulose was obtained from E Merck AG, Darmstadt, West Germany. Standard disposable glass bacteriological test tubes (75 x 12 mm) can be obtained from any general supplier and were used as received.
ASSAY BUFFER AND DEXTRAN-COATED

CHARCOAL
The assay buffer comprised 0·01 M phosphate/G-15 M NaCl (pH 7,4) containing gelatin (0,1 % w/v) prepared in deionised water. Dextran-coated charcoal suspension was prepared by dissolving Dextran T-70 (0,25% w/v) in assay buffer followed by the addition of Norit A charcoal (0·25% w/v). A fine suspension was obtained with mixing by means of a magnetic stirrer. This suspension was prepared at least 1 hour before use, and stirring was maintained (in an ice bath) while aliquots were removed during the assay.
REAGENTS FOR RADIOIMMUNOASSAY
All common solvents and reagents (Analar Grade) were purchased from BDH Chemicals Ltd, Poole, Dorset, UK, with the exception of ethanol, which was obtained from James Burroughs Ltd, London, UK. Ethinyl oestradiol, bovine serum albumin (Cohn Fraction V), Norit A charcoal, and gelatin were all obtained from Sigma, London, UK. 37
ETHINYL OESTRADIOL SOLUTIONS
A stock standard solution of EE 2 , 1 mg in 10 ml ethanol, was stored at 4°C. Subsequent dilution with ethanol provided the working standards used in the dose response curve: 10, 20, 30, 50, 80 , and 100 pg EE 2 in 100 fLl of ethanol. Radioligand (6, 7-3H)-ethinyl oestradiol (specific activity 58·3 Ci/mmol) was obtained from NEN Chemicals, Gmbh, Dreieich, West Germany, and diluted on receipt in benzene/methanol (9/1 by vol). This stock solution was stored at 4°C for not longer than four months. Tritiated EE 2 solution, for use in the assay, was prepared when required by drying an aliquot (50 !J.l) of the stock tritiated-ligand solution under nitrogen and dissolving the residue in 30 ml of assay buffer. The 100 !J.l aliquots of this solution used in the assay contained approximately 12000 dpm.
ANTI-ETHINYL OESTRADIOL SER UM
This was raised in New Zealand White rabbits against an ethinyl oestradiol-6-(Q-carboxymethyl)oxime/BSA conjugate prepared by the method of Erlanger et al. 3 Rabbits were immunised as described by Hillier et al. 4 The antiserum was diluted in assay buffer 0/100) and stored in 1·0 ml aliquots at -20°C. An aliquot was thawed and diluted to 1/3000 with assay buffer before use in the assay.
SOLID-PHASE ANTI-OESTRADIOL SER UM
The anti-oestradiol serum used to extract EE 2 from plasma samples was kindly donated by Dr B Furr and was raised in goats against an oestradiol-17h ernisuccinate/BSA conjugate. This antiserum was coupled to microcrystalline cellulose, activated by cyanogen bromide, by the method of Wide. s Solidphase antiserum, suitably diluted in assay buffer (1/100), was stable on storage at 4°C for at least six months. This was diluted to 1/300 with assay buffer before use in the extraction procedure.
ETHANOL TREATMENT OF SOLID-PHASE
ANTI-OESTRADIOL SER UM
It was necessary to remove endogenous antibodybound oestradiol from the solid-phase antiserum before use in the 'extraction' procedure. The antiserum (10 ml; 1/100) was centrifuged and the buffer was discarded. Ethanol (5 ml) was added to the cellulose pellet and the tube was vortexed for 1 minute. The tube was again centrifuged and the ethanolic supernatant was decanted. This procedure was repeated four times, and the antiserum was then washed twice and finally resuspended in assay buffer (10 ml). Each ethanol wash was evaporated and the oestradiol content was determined. Oestradiol was undetectable in the fourth and fifth ethanol washes. This procedure caused little change in antiserum titres.
RADIOIMMUNOASSAY PROCEDURE USING A SOLID-PHASE ANTISER UM (IMMUNOSORBENT) EXTRACTION Plasma aliquots (300 !J.l) were dispensed into Dyas, Turkes, Read, and Riad-Fahmy disposable glass assay tubes (75 x 12 mm), and solid-phase anti-oestradiol serum (300 ul), suitably diluted, was added. The tubes were vortexed briefly and incubated overnight at 4°C. Assay buffer (3 ml) was added, and the tubes were centrifuged for 5 minutes, the supernatant then being removed by inversion. This procedure was repeated with a further 3 ml of assay buffer, and ethanol (300 !J.l) was then added to the solid-phase pellet and the tubes were mixed on a multi-vortex mixer (Baird & Tatlock) for 10 minutes. After centrifugation for 10 minutes, aliquots (200 !J.l) of the ethanolic supernatants were dispensed into clean assay tubes. The ethanol extracts and working standards (100 ul) were then evaporated under nitrogen at 30°C. Anti-EE 2 serum (100 !J.l) was added and the tubes were vortex-mixed briefly. After a 3D-minute incubation at room temperature, tritiated EEs olution (100 !J.l) was added and the tubes were incubated at 30°C for 1 hour. The tubes were then transferred to an ice-bath, and 500 !J.l of a wellstirred, ice-cold, dextran-coated charcoal suspension was added to effect separation of free and bound steroids. After standing for 17 minutes, the tubes were centrifuged at 1500 g for 10 minutes, and the supernatants were tipped into disposable scintillation vials. Scintillant (6 ml) was added, and the radioactivity associated with the antibody-bound fraction was counted. The unknown EE 2 concentrations were interpolated from the dose response curve using the four parameter fit model of Rodbard and Hutt."
Results
ANALYTICAL VARIABLES
The dose response curve obtained in the radioimmunoassay is shown in Figure 1 . Replicate assays (n = 10), processed in one day, established that the precison of the standard curve was satisfactory at all fixed points; coefficients of variation of the response metameter did not exceed 4· 7 %.
The sensitivity of the standard curve, defined here according to Kaiser and Specker? as the least amount distinguishable from zero at the 95 % confidence level, was 1· 3 pg.
Specificity
The cross-reactivity of EE 2 and other structurally related steroids was assessed by the criteria of Abraham." The data, shown in Table I Analytical recovery Tritiated EE 2 was added to plasma samples and allowed to equilibrate overnight at 4°C. Recovery, using the 'imrnunosorbent extraction' technique, was 97· 6 ± 1· 6 (n = 6). The addition of 'tracer' was therefore considered unnecessary for the routine determination of EE 2 concentrations in unknown samples.
The addition of 0, 10,20,30,50, and 100 pgj300 fl.l ofEE 2 to male plasma, equilibration, and subsequent analysis provided the data shown in Figure 2 . Recovery was again excellent. Analysis of male plasma, or plasma from females not routinely taking oral contraceptives, consistently gave results that were not distinguishable from zero. This finding is in contrast to those of other published radioimmunoassays using solvent extraction where high plasma 30-...............-.....--. . . --. 
Cross-reactivity (%) Steroid
Precision
Three plasma pools of high, medium, and low EE 2 concentrations were established. Ten aliquots were assayed, and the results were used to assess intraassay variations (Table 2) . These pools were subsequently split into aliquots, stored at -20 o e, and used as quality controls for subsequent assays, and to assess inter-assay variation ( 
The assay has been shown to conform to accepted validation criteria and has subsequently been used to measure EE 2 concentrations in plasma samples from subjects undergoing pharmacokinetic and bioavailability studies. Normal, healthy volunteers (n = 3) had blood samples taken over a period of 24 hours after the oral administration of a preparation containing EE 2 (35 fLg) and norethisterone (500 fLg). The plasma EE 2 concentrations found in this study are shown in Figure 4 . Peak levels were found within 2 hours of administration and ranged from 500 to 580 pmol/I, Plasma EE 2 was still detectable at 24 hours in two subjects but not in the third subject in whom the concentration was less than 20 pmol/I. The current use of contraceptive preparations containing low-dose EE 2 has necessitated the development of sensitive immunoassays, While radioimmunoassays for the measurement of this steroid in plasma have been reported,9--13 gross variations in the concentration of plasma EE 2 have been noted, particularly when EE 2 has been administered with a gestagen in combined contraceptive preparations. Pasqualini et aI. o noted peak levels ranging from 405 to 3580 pmol/I in subjects receiving 50 fLg EE 2 in combination with 1000 fLg norethisterone or its acetate. Similarly, peak values of around 3380 pmol/l were observed by Elstein et al. 12 in subjects taking a combined low-dose preparation containing 30 fLg EE 2 and 150 fLg d-norgestreI. The values are much higher than those reported in this study (500--580 prnol/l) in which subjects were given preparations containing 35 fLg EE 2 and 500 fLg norethisterone. Pasqualini et al. o and Elstein et al. 12 do not state any cross-reactivity tests between the EE 2 antisera and the gestagen used. Lahteenmaki and Nilsson-" found peak plasma EE 2 levels ranging from 220 to 540 prnol/l in three women taking 30 fLg EE 2 and 150 fLg d-norgestrel. These results are comparable with those reported here but are higher than those reported by Nilsson and Nygren'? in subjects taking 30 and 50 fLg of EE 2 alone; using the same antiserum and tracer as Lahteenrnaki and Nilsson they reported concentrations of 170-340 and 320-456 pmol/l. It is possible that higher concentrations of apparent EE 2 seen in subjects receiving 12 concomitant progestagens represent EE 2 and the corresponding IS-methyl EE 2 formed from norethisterone and norgestrel respectively. However the conversion of norethisterone and norgestrel to phenolic steroids in significant amounts remains controversial, and the topic is reviewed elsewhere.P The immunosorbent extraction procedure described here relies on a non-specific anti-oestrogen serum, raised against 17~-oestradiol 17-hemisuccinate conjugate, which shows high affinity binding for ethinyl oestradiol but not for norethisterone. Bound oestrogens are eluted with ethanol, then determined using an anti-ethinyl oestradiol serum which shows good selectivity with respect to oestradiol. Use of this extraction procedure conferred specificity on a radioimmunoassay system using a relatively non-specific antiserum, allowing the quantitative determination of ethinyl oestradiol in plasma samples from subjects taking combined oral contraceptive preparations.
